0001429260 false --12-31 0001429260 2021-06-17 2021-06-17 0001429260 us-gaap:CommonStockMember 2021-06-17 2021-06-17 0001429260 fbio:Sec9.375SeriesCumulativeRedeemablePerpetualPreferredStockMember 2021-06-17 2021-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 17, 2021

 

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 (State or Other Jurisdiction

of Incorporation)

 

 

001-35366

 (Commission File Number)

 

 

20-5157386

(IRS Employer Identification No.)

 

2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act.

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock FBIO Nasdaq Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

As described under Item 5.07 of this report, on June 17, 2021, the stockholders of the Company voted at the 2021 Annual Meeting to approve amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 20,000,000 shares, bringing the total number of authorized shares of common stock to 170,000,000 shares (the “Authorized Shares Amendment”).

 

On June 23, 2021, following the 2021 Annual Meeting, the Company filed a certificate of amendment giving effect to the Authorized Shares Amendment with the Secretary of State of the State of Delaware. A copy of the certificate of amendment giving effect to the Authorized Shares Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.03.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 17, 2021, the Company held its 2021 Annual Meeting of stockholders at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. Stockholders representing 73,584,058 shares of the Company’s common stock, or 75.66%, of the 97,253,892 shares entitled to vote, were represented in person or by proxy, constituting a quorum.

 

At the 2021 Annual Meeting, the following three proposals were approved: (i) the election of eight directors to hold office until the 2021 annual meeting; (ii) an amendment to Fortress’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 20,000,000 shares from 150,000,000 shares to 170,000,000 shares; (iii) the ratification of the appointment of BDO USA, LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2021. The three proposals are described in detail in Fortress’s definitive proxy statement on Schedule 14A for the 2021 Annual Meeting filed with the SEC on April 30, 2021.

 

Proposal 1

 

The votes with respect to the election of eight directors to hold office until the 2022 annual meeting were as follows:

 

Director   Votes For     % Voted For     Votes
Withheld
    % Voted
Withheld
    Broker
Non-Votes
 
Lindsay A. Rosenwald, M.D.     52,412,097       97.84 %     1,157,875       2.16 %     20,014,086  
Michael S. Weiss     50,141,156       93.60 %     3,428,816       6.40 %     20,014,086  
Eric R. Rowinsky, M.D.     48,280,089       90.13 %     5,289,883       9.87 %     20,014,086  
J. Jay Lobell     37,484,820       69.97 %     16,085,152       30.03 %     20,014,086  
Jimmie Harvey, Jr., M.D.     52,828,230       98.62 %     741,742       1.38 %     20,014,086  
Dov Klein, C.P.A.     49,443,326       92.30 %     4,126,646       7.70 %     20,014,086  
Malcolm Hoenlein     45,697,154       85.30 %     7,872,818       14.70 %     20,014,086  
Kevin L. Lorenz, J.D.     49,404,316       92.22 %     4,165,656       7.78 %     20,014,086  

 

Proposal 2

 

The vote with respect to the approval of an amendment to Fortress’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 20,000,000 shares from 150,000,000 shares to 170,000,000 shares was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 71,134,130    2,383,026    66,902    0 

 

 

 

 

Proposal 3

 

The vote with respect to the ratification of BDO USA, LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2021 was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 73,231,828    327,603    24,627    0 

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are filed as part of this report:

 

Exhibit
Number
  Description
     
3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc.
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Fortress Biotech, Inc.
  (Registrant) 
   
Date: June 23, 2021    
     
  By: /s/ Lindsay A. Rosenwald, M.D.
    Lindsay A. Rosenwald, M.D.
    Executive Chairman, President and Chief Executive Officer